Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue

Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue
Gilead Sciences Inc. (NASDAQ:GILD) has taken the decision to limit the number of patients it admits to its support path patient assistance program. The decision only affects those patients seeking access to the company's HCV drugs, Harvoni and Sovaldi.
Read more here.

Ally Financial tops 2Q profit forecasts
Specifically, investors is going to be seeking comments from Merck about the advancement of its total hepatitis C pipe – recall, Merck registered to get a new medication request because of its HCV combination remedy of grazoprevir and elbasvir in-May …
Read more here.
Truthdigger of the Week: Covered California
“I'm just wondering if there's some way we can leverage that, to have some impact on the drug companies.” After realizing that new hepatitis C drugs would cost the state more than $ 200 million in the next fiscal year, Gov. Jerry Brown called for the …
Read more here.

Doctors Object to High Cancer-Drug Prices
Members of Congress have demanded that pharmaceutical companies justify the pricing of hepatitis C medication, which costs tens of thousands of dollars per patient. Sen. Bernie Sanders has advised the Department of Veterans Affairs to break the patents …
Read more here.
World Hep Day raises awareness in lakecity
The disease, which is treatable, can be contracted through shared drug equipment, unprotected sex and sharing household razors or toothbrush with someone infected, to name a few. “The message is everybody needs to get a baseline Hep C test,” said Day.
Read more here.

New cholesterol drug gets approved for patients with heart disease, genetic risks
CVS and other large payers such as Express Scripts put pressure on Gilead Sciences to lower the price of its $ 1,000 hepatitis C pill after it was launched in late 2013. Gilead was forced to discount its price after a rival drug from AbbVie emerged late …
Read more here.
Heroin: The Epidemic That Knows No Boundaries
Medication-assisted treatment has been shown to improve social functioning and reduce risky behaviors that transmit infectious diseases such as HIV and hepatitis C. Heroin use is increasing across nearly all populations, and there is a connection to …
Read more here.

Merck tops Street 2Q forecasts despite lower sales, profit
The Kenilworth, New Jersey-based company noted experimental hepatitis C combination pill grazoprevir/elbasvir is now being reviewed by regulators in the U.S. and European Union. Hepatitis C is now one of the hottest areas in medicine, with a new …
Read more here.
AbbVie Sales Fall Short of Estimates as Biggest Drug Misses
The drugmaker also has a hepatitis C treatment, Viekira Pak, that generated $ 385 million in sales in the second quarter, compared with an average estimate of $ 370 million. While Viekira sales were better than expected, the underlying number of …
Read more here.

Billion Dollar Drugs: America's 10 Top Selling Medications
Advances in medical research mean that more specialty drugs could be hitting the market soon. A new class of cholesterol drugs slated for approval later this year could generate more than $ 1.5 billion in sales per year. Unlike the Hepatitis C treatment …
Read more here.
Babesia infection caused by ticks
The blood tests for Babesia rarely identify it and treatment is difficult. But not knowing about Babesia is also difficult because you wind up taking medications for 10 different symptoms that might be related to one single infection. Focusing on …
Read more here.

10 Essential Facts About Hepatitis C
Hepatitis C is a viral infection that damages your liver over time. A chronic infection can lead to serious scarring of the liver called cirrhosis, as well as liver cancer and liver failure, according to the American Liver Foundation (ALF). Hepatitis C …
Read more here.


Leave a Reply